🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

It's #SunAwarenessWeek! ☀️ Did you know that sunscreen is classed as a luxury item in the UK meaning that you pay VAT to protect your skin. Melanoma Focus is calling for the UK Government to abolish VAT on factor 30+ sunscreen. Learn more, here👉buff.ly/1gTM4xl

Great to see ctDNA NGS is now fully funded by NHS England for routine blood draw at presentation of advanced #NSCLC to clinic or as emergency admission tinyurl.com/ykd2bn96 Now we need max implementation for max benefit! BTOG British Thoracic Society (BTS) Lung Cancer Nursing UK

Explore the latest progress in treating #SCLC with Jacob sands at our upcoming roundtable, including emerging data on immuno-oncology #IO combination therapies, plus more with Solange Peters and Giannis Mountzios ⏰ 17th June at 5PM CEST Join the discussion for free ⬇️

“Covariants in KRAS/STK11 or KRAS/KEAP1 were associated with lack of pCR. Patients with single-station or multistation N2/N3 disease exhibited comparable pathological outcomes.” jamanetwork.com/journals/jamao… Biagio Ricciuti, MD, PhD Dana-Farber's Lowe Center for Thoracic Oncology JAMA Oncology #lcam #lcsm

🔥 ESMO Open ESMO - Eur. Oncology 🆙 ✅Efficacy and safety of larotrectinib as first-line treatment for patients with TRK fusion cancer 🎯ORR 77% 🎯DOR 59m 🎯PFS 61m 🎯5-y OS rate 76% 🎙️ David S. Hong MD #LCSM OncoAlert esmoopen.com/article/S2059-…

Bispecific Antibodies in Non–Small Cell Lung Cancer: From Targeted Innovation to Real-World Integration | American Society of Clinical Oncology Educational Book ascopubs.org/doi/10.1200/ED… #LCSM #ASCO25

Landmark OS data from #CheckMate816 just dropped in NEJM! 🫁 Neoadjuvant #Nivolumab + chemo in resectable #NSCLC delivers: ✅ 5-yr OS: 65.4% vs 55.0% ✅ HR: 0.72 (p=0.048) ✅ Lung cancer–specific survival HR: 0.65 ✅ OS with pCR: 95.3% ✅ ctDNA clearers: 75%+ OS 📌 No lung

🔥BREAKING‼️ NEJM 🆙 ✅DeLLphi-304: Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy 🎯Tarlatamab vs chemo 🎯mOS 13.6 vs. 8.3m 🎯OS HR 0.60 (95%CI 0.47-0.77) 🎙️ Giannis Mountzios 🔜 #ASCO25 #LCMS, ORAL, LocoReg/SCLC OncoAlert LARVOL nejm.org/doi/full/10.10…

This is a major story from #ASCO25. Randomized phase 3 trial of time of day of immunotherapy infusion. Randomized to infusion before or after 3pm. Early infusion far superior: PFS 11.3 vs 5.7 HR 0.42, OS HR 0.45! Impactful, pragmatic, not costly. This should be a bigger story.

NeoADAURA, Osi/osi-chemo/chemo neoadj 2 vs 8% PD rate MPR 26 vs 25 vs 2%: benefit across genotype & stage. Greater depth response by osi-chemo>osi Nodal downstaging in both osi arms Osi/osi-chemo reduces PD, gets MPR Impressive EFS by MPR vs not #ASCO25

💥 First trial to demonstrate OS benefit in SCLC in the maintenance setting. Lurbinectedin + Atezolizumab hits in ORR, DoR, PFS, and OS. AEs related to lurbi known tox profile. #LCSM #ASCO25 SmallCellSMASHERS

IMforte: RP3 maintenance lurbi+atezo ES-SCLC CNS+ excluded. Enrolled post #4 chemo-atezo if non-PD. GCSF supported. PFS HR=0.5: 2.1 to 5.5mo OS HR=0.73: 10.6 to 13.2mo (from randomztn) ORR 19.4 vs 10.4mo AEs as expected Bravo: a new standard of care #ASCO25

#ASCO25 After 30 years of failed trials, #tarlatamab changes SoC for our pts with relapsed #SCLC : ✅ mOS: 13.6 vs 8.3 months, HR=0.6, p<0.001 ✅ improved QoL (dyspnea and cough) ✅ 27% vs 62% G3 TRAEs Grateful to all collaborators, Amgen 🧪🔬🧬 science team and above all our pts

Impressive results indeed for China base phase2 trial of BNT327 +chemo in pleural & peritoneal #mesothelioma #ASCO25

📢 Today’s the day! Join our BTOG webinar as we break down the most relevant #ASCO25 updates for UK lung cancer care. 🎯 Key insights 🎙 Expert discussion 🕒 18:00-19:15 | 🔗 btog.org/asco-update-we… See you there! #BTOGASCO2025Webinar #Oncology #LCSM #LungCancer

Got an #NSCLC case or a question on immunotherapy? Share it anonymously and get expert input during our upcoming session with Solange Peters, Jordi Remon, and Patrick Forde. #LCSM ⏰ 25ᵗʰ June at 5:30PM CEST 📩 Submit now to be part of the live discussion ⬇️

Important awareness piece by BBC News (UK) reminding us that lung cancer is on the rise in people who have never smoked. These are different types of lung cancer and we’re still learning why they occur: radon, pollution, unknown. All of us are at risk. bbc.com/future/article…

1/3 🫁 #Afatinib vs Chemotherapy with #Uncommon #EGFR Mutations: ACHILLES/TORG1834 ⭐️ Final OS analysis #ASCO25 Abstract #8623 #egfr #LCSM #uncommon #compound #afatinib

3 weeks after ASCO25, let’s digest the data from the landmark DeLLphi-304 trial published in NEJM that changed the >30 years SoC in recurrent #SCLC from immunobiology and clinical standpoints: 🧵 1/15 #some #LCSM @ASCO IASLC ESMO - Eur. Oncology ETOP IBCSG Partners Foundation EORTC SmallCellSMASHERS

Lung cancer survival more than doubles from 2000-2020 due to the collective efforts of precision medicine, immunotherapy, & early detection - 5015pts w lung adenocarcinoma🇫🇷 - mOS 8.5m (2000) v 20.7m (2020) ⁦OncoAlert⁩ #LCSM evidence.nejm.org/doi/full/10.10…